

Internet news

Dương Xuân Tùng
TMH-MEDIC

OCT 09, 2025

Earflo

Helping kids clear their ears

by Matt Fuchs

MATT FUCHS WRITES ABOUT SCIENCE, HEALTH, AGING, AND WELL-BEING. HIS SUBSTACK IS PRIME FACTORS AND HE IS A 2026-2027 KNIGHT-WALLACE FELLOW.

Courtesy Earflo Inc


1. Device seals around nose
AIR
3. Air assists Eustachian tube opening
2. Soft palate retracts during swallow
4. Effusion drains down Eustachian Tube
5. No fluid remaining in middle ear

a) b)



FDA NEWS RELEASE

FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program

Groundbreaking AAV-based gene therapy offers potential treatment for patients with OTOF gene-associated severe-to-profound and profound hearing loss

More Press Announcements

For Immediate Release: April 23, 2026

The U.S. Food and Drug Administration today approved Otarmeni (lunsotogene parvec-cwha), the first-ever dual adeno-associated virus (AAV) vector-based gene therapy. Otarmeni is indicated for the treatment of pediatric and adult patients with severe-to-profound and profound sensorineural hearing loss (any frequency >90 dB HL) associated with molecularly confirmed biallelic variants in the *OTOF* gene.

Content current as of:
04/23/2026

Follow FDA
Follow @US_FDA
Follow FDA

Eye Test Predicts Consciousness Recovery After Brain Injury: EAN 2026

29 Jun 2026 | Neurology | View All News

A 13-SECOND bedside eye test may help doctors predict which patients regain awareness days after severe brain injury, according to research presented at the European Academy of Neurology Congress 2026, by reading a phase of the pupil's response to light, known as the late light-off response (LOR).

More articles

Flagship Journal
4 Mins • 16 Jun 2026
Novel *LDB3* Variant Identified in Myofibrillar Myopathy

Flagship Journal
10 Mins • 16 Jun 2026
***PER* Genes Connect Circadian Clock Disruption with Diseases**

Otolaryngology–Head and Neck Surgery

AMERICAN ACADEMY OF OTOLARYNGOLOGY-HEAD AND NECK SURGERY FOUNDATION®

Original Research

Fluorescence Spectroscopy for Real-Time Intraoperative Detection of Middle-Ear Cholesteatoma

Joackim Mahdjoub MD, MSc, Olivier Gaiffe PhD, Riham Altaisan MD, Nikolaos Zirganos MD, Nicolas Passilly PhD, Bruno Wacogne PhD, Emmanuel Ramasso PhD, Laurent Tavernier MD, HDR

First published: 22 March 2026 | https://doi.org/10.1002/ohn.70207 | VIEW METRICS

Accessibility issue? Request accessibility update.

Read the full text > PDF CITE TOOLS SHARE

Abstract

Objective

To evaluate whether autofluorescence spectroscopy (AFS) can reliably distinguish cholesteatoma from surrounding middle-ear tissues, and to develop a real-time intraoperative diagnostic tool.

Study Design

Volume 174, Issue 6
June 2026
Pages 1593-1598

References Related Information

1. Yung M, Tono T, Olszewska E, et al. EAONO/JOS joint consensus statements on the definitions, classification and staging of middle ear cholesteatoma. *J Int Adv Otol*. 2017; **13**(1): 1-8. doi:10.5152/iao.2017.3363

PubMed | Web of Science® | Google Scholar

2. Aquino JEAP, Cruz Filho NA, Aquino JNP. Epidemiology of middle ear and mastoid cholesteatomas: study of 1146 cases. *Braz J Otorhinolaryngol*. 2011; **77**(3): 341-347. doi:10.1590/S1808-86942011000300012

PubMed | Google Scholar

ENTtoday
A publication of the Triological Society

What's New Versus Tried and True in Pulsatile Tinnitus

by David Bronstein • June 3, 2026

Obesity may be the engine driving idiopathic intracranial hypertension (IIH), pulsatile tinnitus (PT), and related otologic disorders, with new research pointing to glucagon-like peptide-1 (GLP-1) receptor agonists as a way to tamp the brakes on

ENTtoday is a publication of The Triological Society.

Aidoc's chest X-ray reporting tool earns FDA Breakthrough Device designation

Hannah Murphy | *June 26, 2026* | *Radiology Business* | *Policy & Regulations*

Source: *EDE*

An artificial intelligence-powered tool that assists with chest radiograph interpretation and report drafting has just been granted Breakthrough Device designation from the U.S. Food and Drug Administration.

First Read analyzes chest radiographs and produces high quality draft report text to help radiologists complete interpretations more efficiently while maintaining direct oversight. Chest X-rays are the most frequently performed imaging exam in the world and can account for a significant portion of a radiologist's workload, depending on the setting. Aidoc hopes the product can help ease this burden and allow readers to shift their focus on more complex, time-intensive interpretations.

"Radiology is entering a new era," Elad Walach, CEO and co-founder of Aidoc, said in a statement June 26. "For decades, radiologists have carried growing workloads with tools that were never designed for today's scale of imaging demand. First Read represents an important step toward a future where safe, clinically validated AI can help absorb more of the operational burden, allowing radiologists to focus more of their time on interpretation, judgment and patient care."

AI-designed nasal spray offers broad antiviral protection

TUE 16 DECEMBER 2025 ★ 0

News

terferon-lambda has long been considered a promising therapeutic candidate, but its clinical usefulness has been limited, until now.

Author

Journalistic Team
Editorial staff - ICT&health

MEDICINE

INNOVATION

Eye scans and AI reveal hidden Alzheimer's risks

WED 17 JUNE 2026

0

News

The AI system identified specific retinal regions, including blood vessels and the optic nerve, that were associated with known Alzheimer's risk factors.

Author

Journalistic Team
Editorial staff - ICT&health

AI

DIAGNOSE

RESEARCH

Imaging scan that makes prostate cancer cells glow cuts biopsies

THU 12 MARCH 2026 ★ 0

News

… the study, participants were randomly assigned to receive either a standard biopsy or a PSMA PET/CT scan.

Author

Journalistic Team
Editorial staff - ICT&health

DIAGNOSE
INNOVATION
IMAGING